ORIGINAL ARTICLE

Effect of Thyrotropin Releasing Hormone (TRH) on Gene Expressions in Rat Pancreas: Approach by Microarray Hybridization

Naohiro Yano, LuGuang Luo

Hallett Center for Diabetes and Endocrinology, Rhode Island Hospital, Brown Medical School. Providence, RI, USA

ABSTRACT

Context Thyrotropin releasing hormone (TRH), originally identified as a hypothalamic hormone, expresses in the pancreas. The effects of TRH such as, inhibiting amylase secretion in rats through a direct effect on acinar cells, enhancing basal glucagon secretion from isolated perfused rat pancreas, and potentiating glucose-stimulated insulin secretion in perfused rat islets and insulin-secreting clonal beta-cell lines, suggest that TRH may play a role in pancreas. TRH also enlarged pancreas and increased pancreatic DNA content but deletion of TRH gene expression caused hyperglycemia in mice, suggesting that TRH may play a critical role in pancreatic development; however, the biological mechanisms of TRH in the adult pancreas remains unclear.

Objectives This study explored the effect of TRH on rat pancreas.

Subjects Four male-Sprague-Dawley-rats (200-250 g) were given 10 µg/kg BW of TRH intraperitoneally on 1st and 3rd day and sacrificed on 7th day. Four same-strain rats without TRH injection served as controls.

Main outcome measures Wet pancreatic weights were measured. Pancreatic tissues were homogenized and extracted. The insulin levels of the extracts were measured by ELISA. Total RNA from the pancreases were fluorescently labeled and hybridized to microarray with 1,081 spot genes.

Results TRH increased pancreatic wet weight and insulin contents. About 75% of the 1,081 genes were detected in the pancreas. TRH regulated up 99 genes and down 76 genes. The administration of TRH induced various types of gene expressions, such as G-protein coupled receptors (GPCR) and signal transduction related genes (GPCR kinase 4, transducin beta subunit 5, arrestin beta1MAPK3, MAPK5, c-Src kinase, PKCs, PI3 kinase), growth factors (PDGF-B, IGF-2, IL-18, IGF-1, IL-2, IL-6, endothelin-1) and apoptotic factors (Bcl2, BAD, Bax).

Conclusion Reprogramming of transcriptome may be a way for TRH-regulation of pancreatic cellular functions.

INTRODUCTION

Thyrotropin releasing hormone (TRH) was originally identified as a hypothalamic factor with a key role in regulation of the thyroid axis [1, 2, 3, 4, 5, 6, 7]. It is generally thought that blood glucose levels can be modified by administrating TRH to the central nervous system (CNS) [8, 9, 10, 11, 12, 13, 14].

However, TRH expressed in the pancreas [15] and its actions in the pancreas include inhibition amylase secretion in rats through a direct effect on acinar cells [16], enhancing basal glucagon secretion from isolated perfused rat pancreas [17], and potentiating glucose-stimulated insulin secretion in perfused rat islets and insulin-secreting clonal beta-cell lines [18], suggesting that TRH may have direct biological effects on pancreatic function by modifying the exocrine and endocrine function of pancreas. However, the detailed mechanisms of the effects of TRH on the pancreas have not been fully elucidated.

It is well established that the structural and functional integrity of various cells is under the control of a large number of expressed genes [19]. Thus, changes in the transcription levels of several genes correlate to the state of cells. Therefore, unveiling the effect of TRH on a comprehensive profile of genes in the pancreas may facilitate understanding of the biological role of TRH in the pancreas. To achieve this objective, it is necessary to monitor simultaneously the activities of hundreds transcriptional genes. Since the mid-1990s, cDNA arrays have been used to monitor the expressions of mRNA in multiple genes in response to various conditions and species [20, 21, 22, 23, 24, 25]. This approach has proved to be a useful tool for characterizing and quantifying the simultaneous expression of thousands of genes from specific cell populations or other tissue specimens.

To approach how TRH affects pancreatic function, we achieved TRH *in vivo* stimulation of pancreatic insulin productions using conservative ELISA method, and then conducted a microarray study based on the hybridization of 1,081 DNA mechanically fabricated probes. Each array was hybridized with fluorescently labeled complex targets obtained from rat pancreatic tissue with or without TRH administration. Our study suggests that this approach is not only valuable for large-scale profiling of gene transcription levels and patterns in the pancreas, but more importantly it can be used as identification of some candidate genes that

may be involved in the biology of the pancreas in response to TRH. The data obtained here may serve as a resource to elucidate mechanisms of the biological role of TRH in the pancreas.

METHODS

Animals

Four 8-week-old male Sprague-Dawley rats (200-250 g) were given 10 μg/kg BW of TRH intraperitoneally on the 1st and 3rd day. After 6 hours of fasting, the rats were sacrificed and pancreases were collected on 7th day. An additional four rats of the same age were injected with normal saline and served as controls. The animals were anesthetized with a single dose of intraperitoneal injection of sodium pentobarbital solution (60 mg/kg BW, Sigma, St. Louis, MO, USA). The pancreas was isolated clearly. The whole pancreas was then disconnected and moved onto ice. After being marked with only a number without knowing the treated circumstance, the pancreas was weighed by a digital balance and was snap frozen with liquid nitrogen immediately and stored at -80 °C until use for RNA preparation and for insulin assays.

Insulin ELISA

Pancreatic tissues were collected when we sacrificed the control and TRH-treated rats that we used for microarray study. Insulin concentrations in specimens were measured using Ultra Sensitive Rat Insulin ELISA Kit (Crystal Chem Inc., Downer Grove, IL, USA) according to the vender's instruction. Briefly, insulin standards and appropriately diluted (1:50-1:500) pancreas extracts were added to insulin antibody coated 96 well microplate and incubated for 2 hours at 4 °C. After washing 5 times, anti-rat insulin enzyme conjugate was added to the well and incubated for 30 minutes at room temperature. After washing seven times, enzyme substrate solution was added then incubated up to 45 minutes at room temperature in the dark. The reaction was stopped by the addition of 1 N

Figure 1. RNA isolated from pancreas. The image indicated that the quality RNA from pancreas has been isolated and fluorescence labeling has been applied in this RNA for gene array (C = Control; T = TRH).

sulfuric acid. Absorbance at 450 nm was read with μQuant microplate reader (Bio-Tek Instruments Inc., Winooski, VT, USA) and concentrations were calculated by KC Junior® micro plate reader software (Bio-Tek Instruments Inc., Winooski, VT, USA). The experiment was repeated three times individually, giving a total sample size of 12 observations in each group.

Isolation of Total RNA

Total RNA was extracted from homogenate of frozen pancreatic tissue using TRIzol reagent (Invitrogen Life Technology, Carlsbad, CA, USA), and then treated with DNase I (Promega Corp., Madison, WI, USA) to eliminate potential contamination with residual genomic DNA then stored in ethanol at -20 °C until use (Figure 1).

Preparation Targets and Microarray Hybridization

Four 5 μg sets of total RNA obtained from rats of the same group were mixed together. The combined 20 μg of total RNA was used for target preparation. Monofunctional cyanine fluorescent dyes (Cy3 and Cy5; Amersham Pharmacia Biotch Inc., Piscataway, NJ, USA) labeled cDNA targets

were generated using Atlas Glass Fluorescent Labeling Kit (BD Bioscience Clontech, Palo Alto, CA, USA). Cy3 labeled reference target and Cy5 labeled experimental target were mixed together and hybridized to Rat Glass Microarray 1.0 (BD Bioscience Clontech, Palo Alto, CA, USA). The slides were soaked with the target solution in a hybridization chamber that provided with the array kit for 16 hours at 50 °C. After the incubation, the slides were washed for 4 times under stringent condition and then dried. Hybridized signals were scanned using microarray slide scanner (ScanArray, Perkin Elmer Lifescience, Boston, MA, USA). Strength of the signal was normalized as a ratio to the total fluorescence from all 1,081 spots as described elsewhere [26].

Microarray Analysis

To establish the comprehensive transcriptional profile of the rat pancreas, the fluorescent-labeled cDNA target generated from each specimen was hybridized to glass microarray with 1,081 genes. Identification of the expressed genes was based on a distinct position in the microarray. The gene assignment is available on Clontech web site (http://www.bdbiosciences.com/ptProduct.jsp ?backLink=ptProductList.jsp&backName=Pr oduct%20List&prodId=206131). Strength of the signal was normalized as a ratio to the total fluorescence from all 1,081 spots. In order to minimize bias arising from treatment-independent variation in gene expression, three sets of cDNA targets were prepared from one sample and separately hybridized to the microarray. The difference in signal strength among the three hybridizations was compared gene by gene. Genes that displayed inconsistency greater than threefold normalized density validations between hybridization were excluded from the analysis.

Expressed Sequence Tag (EST) Clones

EST cDNA clones including a fragment of genes in pT7T3D-Pac vector were purchased from Invitrogen Life Technology (Carlsbad,

Figure 2. Pancreases from TRH-treated rat (10 µg/kg body weight intraperitoneally at day 1 and day 3 and pancreas collection at day 7) showed significantly increased wet weight than those from controls (1,644±116 mg vs. 1,394±123 mg, TRH vs. control, mean±SD, n=4 in each group; P=0.025).

CA, USA). Clones were seeded on ampicillin-containing LB agar plate and a single colony that grew on the plate was picked up and its insert was amplified by PCR using universal PCR primers. The sequences of the PCR primers are as follows; T7-95 upper primer, 5'-TTA ATA CGA CTC ACT ATA GGG-3', T3-94 lower primer, 5'-AAT TAA CCC TCA ATA AAG GG-3'.

Northern Blotting

Total 10 µg RNA from each sample was run on 1% agarose gel including 1x MOPS and 2.2 M formaldehyde, then transferred to positively charged nylon membrane (Immobilon-Ny+; Millipore, Billerica, MA, USA). After transfer, RNAs were immobilized on the membrane using an automated UV crosslinker (Stratagene, La Jolla, CA, USA). PCR products from EST clones were run on agarose gel and extracted for purification. Purified PCR products were labeled with d-CTP[alpha-^{32}P] (ICN Pharmaceutical Inc., Bryan, OH, USA) using Random Primers DNA labeling Systems (Invitrogen Life Technology, Carlsbad, CA, USA) and hybridized to the RNA membrane in 50% formamide hybridization buffer for 16 hours at 65 °C with continuous rotation. After the hybridization, the membranes were washed 4 times under high stringent condition

and exposed to BioMax MS High-Sensitivity Film (Eastman Kodak Co., Rochester, NY, USA) at -80 °C for development.

Image Analysis

Images from the array hybridizations were captured and quantified using ArrayVision software (Perkin Elmer Lifescience, Boston, MA, USA). All the calculation and statistics handling were performed on Microsoft Excel (Microsoft, Seatle, WA, USA).

ETHICS

The pancreas tissues were harvested in compliance with an approved Rhode Island Hospital Animal Welfare Committee and Use Committee Protocol.

STATISTICS

Statistical significance for pancreatic weight and insulin ELISA data were tested in SPSS 8.0 (SPSS Inc., Chicago, IL, USA) using the Student-t test and reported as mean±SD. Two-tailed P values less than 0.05 were considered statistically significant.

RESULTS

Pancreatic Weight

The weight of the wet pancreas was measured immediately after dissections. TRH significantly increased the weight of the wet pancreas (1,644±116 mg, n=4) in comparison to control rats (1,394±123 mg, n=4; P=0.025) (Figure 2).

Insulin ELISA

We measured insulin levels in rat pancreatic tissue extracts to evaluate the effects of TRH on insulin synthesis. As shown in Figure 3, TRH significantly increases insulin in pancreas tissue extracts (2,412±845 ng/mg vs. control 855±115 ng/mg, normalized with protein concentrations in the extracts; n=12 in each group; P<0.001).

Figure 3. ELISA for rat pancreatic insulin content. Samples were collected simultaneously when sacrificing rats (7th day of TRH treatment). Insulin contents in pancreases were normalized with protein concentration of the extracts. Pancreas extracts from TRH-treated rats contained higher amounts of insulin than controls (2,413±845 ng/mg vs. 855±115 ng/mg, mean±SD normalized; n=12 in each group; P<0.001).

Microarray Analysis

About 60-75% genes of the 1,081 genes were detected in each sample. Genes showing more than three folds difference in response to TRH treatment were counted as differentially expressed genes. The genes were classified into functions (Table 1). TRH significantly enhanced expressions of transcription proteins, oncogenes and tumor suppressors, stress response proteins, metabolism enzymes, apoptosis-associated proteins and DNA binding and chromatin proteins while suppressing immune system proteins, trafficking/targeting proteins and intracellular transducers/effectors/modulators (Tables 2 and 3).

Reconfirmation of Gene Expressions by Northern Blotting

Eight individual genes (calmodulin dependent proteinkin kinase II, arrestin-beta1, G-protein-beta1, bcl-associated protein X, G-protein coupling receptor kinase 2, MAPK-6, n-myc, GABA-A receptor1) were reconfirmed by northern blotting. The total RNA that was used for northern analysis was taken from the same stock of RNA that we used for microarray hybridization. Probes were prepared by a random priming method using UI-EST cDNA clone as described in method section. Three screens were prepared and hybridization and stripping (using 0.4 N

Table 1. Functional classification of differentially expressed gene.

Classification Name	Total[a]	UP[b]	Down[c]
Cell surface antigens	14	1 (7.1%)	0 (0.0%)
Transcription proteins	47	9 (19.1%)	3 (6.4%)
Cell cycle proteins	23	4 (17.4%)	3 (13.0%)
Cell adhesion proteins	36	2 (5.6%)	2 (5.6%)
Immune system proteins	21	1 (4.8%)	2 (9.5%)
Extracellular transport/carrier proteins	14	2 (14.3%)	1 (7.1%)
Oncogenes and tumor suppressors	27	5 (18.5%)	1 (3.7%)
Stress response proteins	70	9 (12.9%)	0 (0.0%)
Membrane channels and transporters	176	12 (6.8%)	10 (5.7%)
Trafficking/targeting proteins	78	4 (5.1%)	7 (9.0%)
Metabolism enzymes	174	26 (14.9%)	11 (6.3%)
Post-translational modification proteins	14	1 (7.1%)	1 (7.1%)
Apoptosis-associated proteins	17	3 (17.6%)	0 (0.0%)
DNA binding and chromatin proteins	11	2 (18.2%)	0 (0.0%)
Receptors (by ligands)	217	13 (6.0%)	10 (4.6%)
Extracellular communication proteins	88	6 (6.8%)	6 (6.8%)
Intracellular transducers/effectors/modulators	216	12 (5.6%)	21 (9.7%)
Involved in protein turnover	78	7 (9.0%)	6 (7.7%)
Receptors (by activities)	110	5 (4.5%)	10 (9.1%)
Cytoskeleton/motility proteins	16	3 (18.8%)	3 (18.8%)
Functionally unclassified	13	1 (7.7%)	3 (23.1%)
DNA synthesis, recombination, and repair proteins	8	3 (37.5%)	1 (12.5%)

[a] Total numbers of genes on the microarray
[b] Numbers of up-regulated genes
[c] Numbers of down-regulated genes

Table 2. Genes up-regulated by TRH.

Control	TRH	Ratio[a]	Gene name
Transcription proteins			
0.000	11.688	-	NF-kappa-B transcription factor p105 subunit (NFKB p105)
0.000	9.319	-	Cellular tumor antigen p53 (TP53)
0.000	1.694	-	Von Hippel-Lindau tumor suppressor protein (VHL)
0.000	1.199	-	Activating transcription factor 2 (ATF2)
0.000	1.036	-	Signal transducer and activator of transcription 3
0.000	0.900	-	Interferon regulatory factor 1
0.000	0.857	-	Growth arrest and DNA damage-inducible protein 153 (GADD153)
0.178	1.033	5.817	C-fos proto-oncogene
0.222	0.675	3.045	Wilms' tumor protein homolog 1 (WT1)
Cell cycle proteins			
0.000	1.492	-	G1/S-specific cyclin C (CCNC)
0.000	0.749	-	Cyclin-dependent kinase 7 (CDK7)
0.000	0.615	-	Wee1 tyrosine kinase
0.437	1.452	3.322	Ccyclin G-associated kinase (GAK)
Extracellular transport/carrier proteins			
0.000	0.501	-	Insulin-like growth factor binding protein, complex acid-labile subunit
0.000	0.236	-	Insulin-like growth factor-binding protein 5
Oncogenes and tumor suppressors			
0.000	9.319	-	Cellular tumor antigen p53 (TP53)
0.000	1.492	-	G1/S-specific cyclin C (CCNC)
0.067	1.062	15.861	Trk precursor
0.160	0.621	3.878	Pim-1 oncogene
0.222	0.675	3.045	Wilms' tumor protein homolog 1 (WT1)
Stress response proteins			
0.000	1.492	-	G1/S-specific cyclin C (CCNC)
0.067	1.062	15.861	Trk precursor
0.160	0.621	3.878	Pim-1 oncogene
0.222	0.675	3.045	Wilms' tumor protein homolog 1 (WT1)
Metabolism enzymes			
0.000	12.952	-	Dopa/tyrosine sulfotransferase
0.000	5.838	-	Acyl-coA oxidase
0.000	3.183	-	Cytochrome P-450 4A1
0.000	1.102	-	Cytochrome b5
0.000	1.025	-	Acyl-Coenzyme A dehydrogenase, short-branched chain
0.000	0.954	-	Adenylate kinase 1 (AK1); ATP/AMP transphosphorylase; myokinase
0.000	0.883	-	Lipoprotein lipase
0.000	0.820	-	UDP-glucuronosyltransferase 8
0.000	0.772	-	Adenylate kinase 3
0.000	0.732	-	Glutathione S-transferase, pi 2
0.000	0.717	-	Cytochrome P-450 2J3
0.000	0.689	-	Acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight-chain
0.000	0.675	-	Cytosolic thymidine kinase (TK1)
0.138	1.785	12.926	Acetyl-CoA acyltransferase, 3-oxo acyl-CoA thiolase A, peroxisomal
0.261	2.665	10.201	Hormone - sensitive lipase, testicular isoform
0.648	5.027	7.756	Mitochondrial ATP synthase beta subunit (ATP5B)
0.565	3.689	6.534	Annexin III (Lipocortin III)
0.178	1.113	6.266	Fructose-1,6- biphosphatase
0.129	0.783	6.056	Cytochrome C, testis specific
0.213	0.985	4.628	Cytochrome P450, 2c39
0.222	0.979	4.419	Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase)
0.217	0.958	4.409	Mitochondrial ATP synthase D subunit; ATP5H
0.169	0.713	4.225	Hepatic triacylglycerol lipase
0.163	0.663	4.062	ATP synthase, subunit c, P2 gene
0.235	0.917	3.904	Mitochondrial hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase
0.450	1.355	3.009	Cytochrom c oxidase subunit VIII-H (heart/muscle)

(Continues)

Table 2. (Continues)

Control	TRH	Ratio[a]	Gene name
Apoptosis-associated proteins			
0.000	9.319	-	Cellular tumor antigen p53 (TP53)
0.000	0.290	-	BCL2-like protein 1 (BCL2L1); BCLX
0.129	0.783	6.056	Cytochrome C, testis specific
DNA binding and chromatin proteins			
0.000	1.210	-	Methyl-CpG-binding protein 2 (MECP2)
0.000	0.609	-	MSH2 DNA mismatch repair protein
Cytoskeleton/motility proteins			
0.000	4.982	-	LIM protein
0.107	0.544	5.068	Syntaxin binding protein 1
0.081	0.282	3.484	Tubulin alpha 1 (TUBA1)
DNA synthesis, recombination, and repair proteins			
0.000	0.609	-	MSH2 DNA mismatch repair protein
0.138	0.498	3.609	O6-methylguanine-DNA methyltranferase
0.169	0.587	3.473	Proliferating cell nuclear antigen (PCNA); cyclin
Intracellular transducers/effectors/modulators			
0.000	0.504	-	Mitogen activated protein kinase kinase 5
0.000	0.453	-	Protein kinase C zeta (PKC-zeta; PKCZ)
0.000	0.362	-	C-Src kinase (CSK)
0.000	0.231	-	Protein kinase C delta type (PKC-delta; PRKCD; PKCD)
0.000	0.219	-	Arrestin, beta 1
0.075	0.550	7.372	Mitogen-activated protein kinase 3 (MAP kinase 3; MAPK3; PRKM3)
0.191	1.389	7.279	G protein-coupled receptor kinase 4 (GRK4)
0.340	2.411	7.084	Serine/threonine kinase 3
0.230	0.974	4.225	Growth factor receptor-bound protein 2 (GRB2)
0.160	0.621	3.878	Pim-1 oncogene
0.178	0.581	3.269	Transducin beta subunit 5
1.193	3.618	3.032	Iinositol 1,4,5-triphosphate 3-kinase (IP3 3-kinase)
Extracellular communication proteins			
0.000	2.027	-	Tyrosine kinase receptor ligand 2
0.000	1.005	-	Platelet-derived growth factor B subunit (PDGFB; PDGF2)
0.000	0.629	-	Interleukin 18
0.000	0.071	-	Insulin-like growth factor II (IGF2)
0.117	0.920	7.863	Insulin-like growth factor binding protein 6
0.604	4.096	6.780	Somatoliberin; growth hormone-releasing factor (GRF)

[a] TRH/control

NaOH) were repeated four or five times. The experiments were repeated at least three times to confirm reproducibility of the results. All the 8 hybridization showed fair consistency to the results from microarray assays. Figure 4 showed representative images for all hybridizations.

DISCUSSION

Pancreatic beta cells possess variable neuronal derivative peptides and hormones that relate them closely with other neuronal derivatives [22, 23, 24, 25, 26, 27, 28, 29].

TRH was originally characterized and has been most extensively studied as a hypothalamic factor with a key role in the thyroid axis [1, 2, 3, 4, 5, 6, 7]. An increasing body of evidence supports the idea that the existence of TRH in the pancreas may affect pancreatic functions [30, 31, 32]. In the present study, we confirmed that TRH-treated rats had increased pancreatic mass in comparison with control rats, which was consistent with previous reports by another group [33], and improved pancreatic endocrine function by promoting beta-cell insulin production *in vivo*. The mechanisms of

Table 3. Genes down-regulated by TRH.

Control	TRH	Ratio[a]	Gene name
Cell cycle proteins			
0.525	0.000	0.000	Cyclin-dependent kinase 2 alpha + cyclin-dependent kinase 2-beta
1.492	0.140	0.094	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta
1.532	0.310	0.203	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
Intracellular transducers/effectors/modulators			
3.128	0.108	0.035	Acyl-CoA hydrolase
1.369	0.000	0.000	Calmodulin III
0.960	0.000	0.000	Protein kinase, cAMP-dependent, catalytic, alpha
1.422	0.342	0.240	Protein kinase, interferon-inducible double stranded RNA dependent
0.393	0.105	0.268	Protein-tyrosine phosphatase
0.274	0.000	0.000	Ras-related small GTP binding protein 4
3.001	0.347	0.116	Ral guanine nucleotide dissociation stimulator
1.442	0.350	0.243	Inositol polyphosphate-5-phosphatase
1.475	0.054	0.037	PI4-K; phosphatidylinositol 4-kinase (92/100 kDa, soluble)
0.833	0.000	0.000	Phosphodiesterase 3B, cGMP-inhibited
0.631	0.000	0.000	Adenylyl cyclase type VI (ADCY6)
1.031	0.000	0.000	Adenylate cyclase 8
1.039	0.000	0.000	Phosphodiesterase 4B, cAMP-specific
0.675	0.151	0.224	Adenylyl cyclase type II
1.532	0.310	0.203	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
1.492	0.140	0.094	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta
1.616	0.530	0.328	V-crk-associated tyrosine kinase substrate
0.178	0.000	0.000	Presenilin 1
0.894	0.000	0.000	GAP-associated protein p190
0.490	0.000	0.000	Fps/fes-related tyrosine-protein kinase (FLK)
0.837	0.000	0.000	Pheochromocytoma-derived protein tyrosine phosphatase-like protein
Extracellular communication proteins			
0.789	0.245	0.310	Non-processed neurexin III alpha
0.200	0.000	0.000	Insulin-like growth factor IB (IGF-IB; IGF1); somatomedin
0.776	0.194	0.250	Prolactin-like protein A
3.251	1.000	0.308	C-type natriuretic peptide (CNP; NPPC)
1.712	0.390	0.228	Natriuretic peptide precursor A, (pronatriodilatin, also Anf, Pnd)
2.042	0.675	0.330	Gonadotropin releasing hormone
1.119	0.259	0.232	Interleukin 2 (IL2)
1.105	0.336	0.304	Interleukin 6 (interferon, beta 2)
0.714	0.134	0.188	Endothelin 1

[a] TRH/control

these distinct experimental findings of TRH action on the pancreas have been approached by the comprehensive pattern of gene transcription.

For the first time, a glass-based microarray with 1,081 cDNA probes has been used to characterize the profile of gene expression pattern and identify differentially expressed genes that responded to TRH in the rat pancreas. Several G-protein coupled receptor related genes (G protein-coupled receptor kinase 4, transducin beta subunit 5, Arrestin, beta1) were up-regulated by TRH. These findings suggest that effects of TRH *in vivo* might evoke G-protein coupled receptor (GPCR) through its cognate, consequently inducing the activation of growth relative signal transduction pathways, MAPKs (MAPK3, MAPK5) and other protein kinases (Pim-1 oncogene, c-Src kinase, protein kinase C delta, protein kinase C zeta, serine/threonine kinase 3 and inositol 1,4,5-triphosphate 3-kinase). The link between GPCR and cellular signal transduction pathways could be beta-arrestins, which are adaptor proteins that form complexes with most GPCRs following agonist binding and phosphorylation of receptors by GPKs [34].

Figure 4. Northern blot images for eight selected genes from rat pancreas. Numbers under images represent normalized density ratios of control/TRH from microarray hybridizations. Each image included both control left and TRH treatment right.

Identifications for the genes are as follows: A1: G-protein beta1 subunit (transducin); A2: arrestin beta1; A3: calcium/calmodulin-dependent protein kinase II; B2: G-protein coupled receptor kinase (GPK) 4; B3: bcl-2 associated X (Bax); C1: gamma-aminobutyric acid (GABA) A receptor; C2: N-myc; C3: MAPK3; beta-actin (bottom row) was served as internal control.

Recent data suggests that beta-arrestins interact directly with Src family tyrosine kinases and components of the ERK1/2 and JNK3 MAP kinase modules suggest that beta-arrestins may function more broadly as adapters to recruit signaling proteins for agonist-occupied GPCRs [35, 36, 37]. We previously reported involvement of Src kinase to TRH-induced trans-activation of EGF receptors in cultured beta cells [38]. The induction of beta-arrestins and c-Src may be a factor in the initiation of the pivotal role of TRH in pancreatic cell bioactivities. Up-regulations of MAPK3 and other protein kinases genes' activities that were observed in the present array study may result in arrestin-related signal transductions leading to cell proliferations.

The proliferating effect of TRH is supposed to be synergistic with growth hormone (GH) [39], and interestingly somatoliberin, also known as growth hormone-releasing factor [40], is up regulated. The other up-regulated (PDGF-B, IGF-2, IL-18, IGF-binding protein 6) or down-regulated (IGF-1, IL-2, IL-6, endothelin-1, gonadotropin releasing hormone, pronatriodilatin, C-type natriuretic peptide, prolactin-like protein A and non-processed neurexin III alpha).

TRH not only stimulates pro-apoptotic gene, p53 but also enhances anti-apoptotic gene, Bcl2-like protein 1 (BclX). The results of gene array from the entire pancreas (a numerous cell types including endocrine and exocrine cells) showed anti and pro apoptotic genes simultaneously enhanced by TRH, which might indicate dual biological actions in different pancreatic cell types. Cells with predominant anti-apoptotic gene expression are subject to survival while others with pro-apoptotic gene expression are subject to apoptosis. The finding could lead to identification of an important mechanism in tissue repair in recovering specific functional cells while prevent over hyperplasia. Although the roles of TRH on pancreatic apoptosis have not been elucidated, this finding indicates that through enhancing anti-apoptotic and pro-apoptotic factors, TRH enlargement of the pancreas could not only activate growth factor like signal transduction pathways, but also stimulate anti-apoptosis pathways. However, TRH activation of pro-apoptotic mechanism could be considered as a compensation for the prevention of over hyperplasia in the pancreas. The specific cell types involved in anti or pro-apoptosis activation induced by TRH requires further investigation.

Our data showed that TRH increased insulin contents in rat pancreas. Although elucidating the meaning of this increase would require more extensive studies, we found some differential expressions of genes that may be related to the synthesis or secretion of insulin. For example, Ca^{2+}/calmodulin-dependent protein kinase (CaM kinase) was not expressed in the control rat pancreas and was induced in the TRH-treated rat. This kinase is known to be required for the activation of voltage-gated calcium channels by cAMP and the increase of Ca^{2+} influx into cytosol [41]. Interestingly, intracellular mobilization of

Ca^{2+} has been disclosed to be tightly related to enhancement of insulin secretion in beta cells [42, 43, 44]. Glutamate receptor gene showed significant enhancement in expression after TRH stimulation (0.584 vs. 0.164, TRH vs. control). This receptor was reported to promote insulin secretion from beta-cell [45]. Although these data are intriguing, considering that the beta-cells occupy only a very small part of the entire pancreas, identifying insulin synthesis/secretion-related genes from the overall pancreas RNA may not be an appropriate way. Studies using isolated islets or beta-cells may elucidate this matter.

The differential gene expression pattern induced by TRH implies that the hypothalamic peptide might have the potential to be a biological regulator for pancreatic cells. Recently, peptide analogues, such as glucagons-like peptide-I, have been applied as a safe and effective candidates for recovery pancreatic beta cell loss [46, 47, 48]. However, how peptides affect gene expressions profile is still unknown and this study provided valuable information for the biological role of peptides in the pancreas.

The present study projects a certain direction to solve the long-lasting argument about the role of TRH in pancreatic functions; however, there are still many genes of which function in beta-cell biology is not fully understood. In addition, we remain concerned about some pit falls generally admitted in microarray hybridization [49].

Abbreviations BAD: Bcl-xL/Bcl-2-associated death promoter; Bax: Bcl-2-associated protein X; Bcl-x: Bcl-like protein-1; EST: expressed sequence tag; GPCR: G-protein coupled receptor; TRH: thyrotropin releasing hormone

Correspondence
LuGuang Luo
Brown Medical School
The Hallett Center for Diabetes and Endocrinology
Rhode Island Hospital
593 Eddy Street
Providence
RI 02903
USA
Phone: +1-401.444.8578
Fax: +1-401.444.3784
E-mail address: lu-guang_luo@brown.edu

References

1. Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun 1969; 37:705-10. [PMID 4982117]

2. Burgus R, Dunn TF, Desiderio D, Guillemin R. Molecular structure of the hypothalamic hypophysiotropic TRF factor of ovine origin: mass spectrometry demonstration of the PCA-His-Pro-HH2 sequence. CR Acad Sci Hebd Seances Acad Sci D 1969; 269:1870-3. [PMID 4983502]

3. Hajjar RA, Anderson MS, Samaan NA. Thyrotropin-releasing hormone as a pituitary-function indicator. A comparison with other tests. Arch Intern Med 1973; 132:836-9. [PMID 4202143]

4. Azizi F, Vagenakis AG, Bollinger J, Reichlin S, Bush JE, Braverman LE. The effect of a single large dose of thyrotropin-releasing hormone on various aspects of thyroid function in the rat. Endocrinology 1974; 95:1767-70. [PMID 4215643]

5. Jackson IM, Reichlin S. Thyrotropin releasing hormine (TRH): distribution in the brain, blood and urine of the rat. Life Sci 1974; 14:2259-66. [PMID 4211252]

6. Jackson IM, Reichlin S. Thyrotropin-releasing hormone (TRH): distribution in hypothalamic and extrahypothalamic brain tissues of mammalian and submammalian chordates. Endocrinology 1974; 95:854-62. [PMID 4212470]

7. Martino E, Lernmark A, Seo H, Steiner DF, Refetoff S. High concentration of thyrotropin-releasing hormone in pancreatic islets. Proc Natl Acad Sci USA 1978; 75:4265-7. [PMID 100783]

8. Amir S, Butler PD. Thyrotropin-releasing hormone blocks neurally-mediated hyperglycemia through central action. Peptides 1988; 9:31-5. [PMID 2896345]

9. Amir S, Harel M, Rivkind AI. Thyrotropin-releasing hormone potently reverses epinephrine-stimulated hyperglycemia in mice. Brain Res 1987; 435:112-22. [PMID 3123010]

10. Amir S. Thyrotropin-releasing hormone (TRH) blocks glucagon-induced hyperglycemia in mice: dissociation of the antihyperglycemic and pituitary actions of TRH. Brain Res 1988; 455:201-3. [PMID 3138000]

11. Amir S, Rivkind AI. Prevention of clonidine-stimulated hyperglycemia by thyrotropin-releasing hormone. Peptides 1988; 9:527-31. [PMID 3138675]

12. Amir S, Rivkind AI, Harel M. Central thyrotropin-releasing hormone elicits systemic hypoglycemia in mice. Brain Res 1985; 344:387-91. [PMID 3930002]

13. Amir S, Jackson IM. Immunological blockade of endogenous thyrotropin-releasing hormone impairs recovery from hyperglycemia in mice. Brain Res 1988; 462:160-2. [PMID 3141004]

14. Masuda M, Kanai S, Miyasaka K. Central somatostatin prevents vagal efferent nerve excitation produced by TRH but not by 2-deoxy-D-glucose. Am J Physiol 1997; 272:G351-6. [PMID 9124360]

15. Dutour A, Giraud P, Kowalski C, Ouafik L, Salers P, Strbak V, Oliver C. Ontogenesis of TRH mRNA in the rat pancreas. Biochem Biophys Res Commun 1987; 146:354-60. [PMID 2955787]

16. Blanco-Molina A, Lopez-Miranda J, Nicolas-Puiggari M, Torre-Cisneros J, Lopez-Segura F, Perez-Jimenez F. Evidence of a direct TRH effect on the exocrine pancreas. Rev Esp Fisiol 1991; 47:173-9. [PMID 1725929]

17. Ebiou JC, Grouselle D, Aratan-Spire S. Antithyrotropin-releasing hormone serum inhibits secretion of glucagon from isolated perfused rat pancreas: an experimental model for positive feedback regulation of glucagon secretion. Endocrinology 1992; 131:765-71. [PMID 1639022]

18. Kulkarni RN, Wang ZL, Akinsanya KO, Bennet WM, Wang RM, Smith DM, et al. Pyroglutamyl-phenylalanyl-proline amide attenuates thyrotropin-releasing hormone-stimulated insulin secretion in perifused rat islets and insulin-secreting clonal beta-cell lines. Endocrinology 1995; 136:5155-64. [PMID 7588254]

19. Schuit F, Flamez D, De Vos A, Pipeleers D. Glucose-regulated gene expression maintaining the glucose-responsive state of beta-cells. Diabetes 2002; 51:S326-32. [PMID 12475771]

20. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with complementary DNA microarray. Science 1995; 270:467-70. [PMID 7569999]

21. Schena M, Shalon, D, Heller R, Chai A, Brown, PO. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 1996; 93:10614-9. [PMID 8855227]

22. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95:15623-8. [PMID 9861020]

23. Yano N, Endoh M, Fadden K, Yamashita H, Kane A, Sakai H, Rifai R. Comprehensive gene expression profile of the adult human renal cortex: analysis by cDNA array hybridization. Kidney Int 2000; 57:1452-9. [PMID 10760081]

24. Yano N, Endoh M, Fadden K, Yamashita H, Sakai H, Kurokawa K, Abboud HE, et al. Genomic repertoire of human mesangial cells: comprehensive analysis of gene expression by cDNA array hybridization. Nephrology 2000; 5:215-23.

25. Yano N, Habib NA, Fadden KJ, Yamashita H, Mitry R, Jauregui H, et al. Profiling the adult human liver transcriptome: analysis by cDNA array hybridization. J Hepatol 2001; 35:178-86. [PMID 11580139]

26. Hegde P, Qi R, Abernathy K, Gay C, Dharap S, Gaspard R, et al. A concise guide to cDNA microarray analysis. Biotechniques 2000; 29:548-56. [PMID 10997270]

27. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001; 292:1389-94. [PMID 11326082]

28. Wolff G, Mastrangeli A, Heinflink M, Falck-Pedersen E, Gershengorn MC, Crystal RG. Ectopic expression of thyrotropin releasing hormone (TRH) receptors in liver modulates organ function to regulate blood glucose by TRH. Nat Genet 1996; 12:274-9. [PMID 8589718]

29. Emanuel RL, Torday JS, Asokananthan N, Sunday ME. Direct effects of corticotropin-releasing hormone and thyrotropin-releasing hormone on fetal lung explants. Peptides 2000; 21:1819-29. [PMID 11150642]

30. Morley JE. Extrahypothalamic thyrotropin releasing hormone (TRH) -- its distribution and its functions. Life Sci 1979; 25:1539-50. [PMID 118318]

31. Engler D, Chad D, Jackson IM. Thyrotropin-releasing hormone in the pancreas and brain of the rat is regulated by central noradrenergic and dopaminergic

pathways. J Clin Invest 1982; 69:1310-20. [PMID 6806317]

32. Aratan-Spire S, Wolf B, Czernichow P. Developmental pattern of TRH-degrading activity and TRH content in rat pancreas. Acta Endocrinol (Copenh) 1984; 106:102-8. [PMID 6428113]

33. Glasbrenner B, Malfertheiner P, Duntas L, Buchler M, Bereiter T, Ditschuneit H. Effects of TRH on pancreatic growth and secretion in rats. Pancreas 1990; 5:37-41. [PMID 1688388]

34. Luttrell LM, Lefkowitz RJ. The role of beta-arrestin in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115:455-65. [PMID 11861753]

35. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999; 283:655-61. [PMID 9924018]

36. Imamura T, Huang J, Dalle S, Ugi S, Usui I, Luttrell LM, Miller WE, et al. Beta -arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport. J Biol Chem 2001; 276:43663-7. [PMID 11546805]

37. Penela P, Elorza A, Sarnago S, Mayor F Jr. Beta-arrestin- and c-Src-dependent degradation of G-protein-coupled receptor kinase 2. EMBO J 2001; 20:5129-38. [PMID 11566877]

38. Luo LG, Yano N, Zhu YH, Smith RJ. Activation of EGF receptors in pancreatic beta cells by thyrotropin releasing hormone (TRH): Cross-talk between neuropeptide and growth factor receptors (Abstract). Diabetes 2002; 51(Suppl 1):A1629.

39. Rhodes CJ. IGF-I and GH post-receptor signaling mechanisms for pancreatic beta-cell replication. J Mol Endocrinol 2000; 24:303-11. [PMID 10828823]

40. Sykes JE, Lowry PJ. Purification of a high-molecular-weight-somatoliberin (growth hormone-releasing factor) from pig hypothalami. Biochem J 1983; 209:643-51. [PMID 6409074]

41. Basavappa S, Mangel AW, Scott L, Liddle RA. Activation of calcium channels by cAMP in STC-1 cells is dependent upon Ca2+ calmodulin-dependent protein kinase II. Biochem Biophys Res Commun 1999; 254:699-702. [PMID 9920804]

42. Takasawa S, Ishida A, Nata K, Nakagawa K, Noguchi N, Tohgo A, et al. Requirement of calmodulin-dependent protein kinase II in cyclic ADP-ribose-mediated intracellular Ca2+ mobilization. J Biol Chem 1995; 270:30257-9. [PMID 8530441]

43. Kiraly-Borri CE, Morgan A, Burgoyne RD, Weller U, Wollheim CB, Lang J. Soluble N-ethylmaleimide-sensitive-factor attachment protein and N-ethylmaleimide-insensitive factors are required for Ca2+-stimulated exocytosis of insulin. Biochem J 1996; 314:199-203. [PMID 8660283]

44. Mohlig M, Wolter S, Mayer P, Lang J, Osterhoff M, Horn PA, et al. Insulinoma cells contain an isoform of Ca2+ / calmodulin-dependent protein kinase II delta associated with insulin secretion vesicles. Endocrinology 1997; 138:2577-84. [PMID 9165051]

45. Bertrand G, Gross R, Puech R, Loubatieres-Mariani MM, Bockaert J. Evidence for a glutamate receptor of the AMPA subtype which mediates insulin release from rat perfused pancreas. Br J Pharmacol 1992; 106:354-9. [PMID 1382779]

46. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR. Glucagon-like peptide-I (GLP-1) – a trial of treatment in noninsulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27:533-6. [PMID 9229235]

47. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-30. [PMID 11897280]

48. Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide I improved glycemic control in type I diabetes. BMC Endocr Disord 2003; 3:3. [PMID 12697069]

49. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr. Microarray results: how accurate are they? BMC Bioinformatics 2002; 3:22. [PMID 12194703]